DOCSLIB.ORG

00643 1619351673.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
00643 1619351673.Pdf 1 Laboratory Chemicals Description Brand Reference Packing 1-(2-PYRIDYLAZO)-2-NAPHTHOL (PAN) METAL INDICATOR REAG. PH EUR Merck 1075310005 5 G CHEMICAL 1,2-Dichlorobenzene for extraction analysis EMSURE® Merck 1029301000 1 L LABORATORY 1,2-Dichlorobenzene for extraction analysis EMSURE® Merck 1029302500 2,5 L 1,4-DIOXANE FOR ANALYSIS EMSURE® ACS,ISO Merck 1096710250 250 ML 1,4-DIOXANE FOR ANALYSIS EMSURE® ACS,ISO Merck 1096711000 1 L 1,4-DIOXANE FOR ANALYSIS EMSURE® ACS,ISO Merck 1096712500 2,5 L 1,4-DIOXANE FOR ANALYSIS EMSURE® ACS,ISO Merck 1096716025 25 L 1-BUTANOL FOR ANALYSIS EMSURE® ACS,ISO,REAG. PH EUR Merck 1019901000 1 L 1-BUTANOL FOR ANALYSIS EMSURE® ACS,ISO,REAG. PH EUR Merck 1019902500 2,5 L 1-BUTANOL FOR ANALYSIS EMSURE® ACS,ISO,REAG. PH EUR Merck 1019906025 25 L 1-NAPHTHOLBENZEIN INDICATOR REAG. PH EUR Merck 1062020005 5 G 1-NAPHTHOLPHTHALEIN INDICATOR Merck 1062460001 1 G 1-NAPHTHOLPHTHALEIN INDICATOR Merck 1062460005 5 G 1-NAPHTHOLPHTHALEIN INDICATOR Merck 1062460100 100G 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096341000 1 L 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096341011 1 L 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096342500 2,5 L 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096342511 2,5 L 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096345000 5 L 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096346010 10 L 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096346025 25 L 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096346190 190 L 2-Propanol for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1096349180 180 L 3-NITROPHENOL INDICATOR Merck 1067940025 25 G 4-NITROPHENOL INDICATOR Merck 1067980025 25 G 4-NITROPHENOL INDICATOR Merck 1067980100 100 G Acetic acid (glacial) 100% anhydrous for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000631000 1 L Acetic acid (glacial) 100% anhydrous for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000631011 1 L Acetic acid (glacial) 100% anhydrous for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000632500 2,5 L Acetic acid (glacial) 100% anhydrous for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000632510 2,5 L Acetic acid (glacial) 100% anhydrous for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000632511 2,5 L Acetic acid (glacial) 100% anhydrous for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000639026 25 L Acetic acid 30% for analysis EMSURE® Reag. Ph Eur Merck 1591660500 500 ML Acetic acid 96% for analysis EMSURE® Merck 1000621000 1 L Acetic acid 96% for analysis EMSURE® Merck 1000621011 1 L Acetic acid 96% for analysis EMSURE® Merck 1000622500 2,5 L Acetic acid 96% for analysis EMSURE® Merck 1000622511 2,5 L Acetic acid 96% for analysis EMSURE® Merck 1000629025 25 L Acetic anhydride for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000421000 1 L Acetic anhydride for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000422500 2,5 L Acetic anhydride for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000429025 25 L Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000141000 1 L Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000141011 1 L Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000142500 2,5 L Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000142511 2,5 L Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000145000 5 L Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000146010 10 L Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000146025 25 L Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000146190 190 L 2 Laboratory Chemicals LABORATORY CHEMICAL CHEMICAL Description Brand Reference Packing Acetone for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1000149180 180 L Acetonitrile for analysis EMSURE® ACS,Reag. Ph Eur Merck 1000031000 1 L Acetonitrile for analysis EMSURE® ACS,Reag. Ph Eur Merck 1000032500 2,5 L Acetonitrile for analysis EMSURE® ACS,Reag. Ph Eur Merck 1000036010 10 L Acetonitrile for analysis EMSURE® ACS,Reag. Ph Eur Merck 1000036025 25 L Acetylacetone for analysis EMSURE® Merck 1096000100 100 ML Acetylacetone for analysis EMSURE® Merck 1096000500 500 ML Alizarin red S mono sodiumsalt (C.I. 58005) for analysis and indicator Merck 1062780025 25 G Alizarin red S mono sodiumsalt (C.I. 58005) for analysis and indicator Merck 1062780100 100 G ALKALI BLUE (C.I. 42765) INDICATOR Merck 1091960025 25 G Alkali blue solution indicator Merck 1091981000 1 L Alkali blue solution indicator Merck 1091982500 2,5 L Aluminium (foil) for analysis 0.3 mm thickness, 30 mm width EMSURE® Merck 1010570250 250 G Aluminium (foil) for analysis 0.3 mm thickness, 30 mm width EMSURE® Merck 1010571000 1 KG Aluminium ammonium sulfate dodecahydrate for analysis EMSURE® ACS Merck 1010310500 500 G Aluminium fine powder, stabilized about 2% fat Merck 1010560250 250 G Aluminium fine powder, stabilized about 2% fat Merck 1010561000 1 KG Aluminium nitrate nonahydrate for analysis EMSURE® Merck 1010630500 500 G Aluminium potassium sulfate dodecahydrate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1010471000 1 KG Amidosulfuric acid for analysis EMSURE® Merck 1001030100 100 G Amidosulfuric acid for analysis EMSURE® Merck 1001030250 250 G Ammonia solution 25% for analysis EMSURE® ISO,Reag. Ph Eur Merck 1054321000 1 L Ammonia solution 25% for analysis EMSURE® ISO,Reag. Ph Eur Merck 1054321011 1 L Ammonia solution 25% for analysis EMSURE® ISO,Reag. Ph Eur Merck 1054322500 2,5 L Ammonia solution 25% for analysis EMSURE® ISO,Reag. Ph Eur Merck 1054325000 5 L AMMONIA SOLUTION 28-30% FOR ANALYSIS EMSURE® ACS,REAG. PH EUR Merck 1054231000 1 L AMMONIA SOLUTION 28-30% FOR ANALYSIS EMSURE® ACS,REAG. PH EUR Merck 1054232500 2,5 L AMMONIA SOLUTION 28-30% FOR ANALYSIS EMSURE® ACS,REAG. PH EUR Merck 1054239025 25 L Ammonium acetate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1011160500 500 G Ammonium acetate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1011161000 1 KG Ammonium acetate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1011165000 5 KG Ammonium acetate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1011169012 12KG Ammonium acetate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1011169025 25 KG AMMONIUM BROMIDE FOR ANALYSIS EMSURE® ACS Merck 1011251000 1 KG AMMONIUM BROMIDE FOR ANALYSIS EMSURE® ACS Merck 1011259025 25 KG Ammonium carbamate for analysis EMSURE® Merck 1011340500 500 G Ammonium carbonate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1595040250 250 G Ammonium carbonate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1595041000 1 KG Ammonium cerium(IV) nitrate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1022760100 100 G Ammonium cerium(IV) nitrate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1022761000 1 KG Ammonium cerium(IV) sulfate dihydrate for analysis EMSURE® ACS Merck 1022730100 100 G Ammonium chloride for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1011450500 500 G Ammonium chloride for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1011451000 1 KG Ammonium chloride for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1011455000 5 KG Ammonium chloride for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1011459025 25 KG Ammonium chloride for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1011459050 50 KG Ammonium dihydrogen phosphate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1011260500 500 G Ammonium dihydrogen phosphate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1011265000 5KG Ammonium dihydrogen phosphate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1011269050 50 KG 3 Laboratory Chemicals Description Brand Reference Packing Ammonium fluoride for analysis EMSURE® ACS Merck 1011640250 250 G CHEMICAL Ammonium fluoride for analysis EMSURE® ACS Merck 1011641000 1 KG LABORATORY Ammonium fluoride for analysis EMSURE® ACS Merck 1011649025 25 KG Ammonium iron(II) sulfate hexahydrate for analysis EMSURE® ISO Merck 1037920500 500 G Ammonium iron(II) sulfate hexahydrate for analysis EMSURE® ISO Merck 1037921000 1 KG Ammonium iron(II) sulfate hexahydrate for analysis EMSURE® ISO Merck 1037925000 5 KG Ammonium iron(II) sulfate hexahydrate for analysis EMSURE® ISO Merck 1037929050 50 KG AMMONIUM IRON(III) SULFATE DODECAHYDRATE EMSURE® ACS,ISO,REAG. PH EUR Merck 1037760500 500 G AMMONIUM IRON(III) SULFATE DODECAHYDRATE EMSURE® ACS,ISO,REAG. PH EUR Merck 1037761000 1 KG AMMONIUM IRON(III) SULFATE DODECAHYDRATE EMSURE® ACS,ISO,REAG. PH EUR Merck 1037765000 5 KG AMMONIUM IRON(III) SULFATE DODECAHYDRATE EMSURE® ACS,ISO,REAG. PH EUR Merck 1037769050 50 KG Ammonium nitrate for analysis EMSURE® ACS Merck 1011880500 500 G Ammonium nitrate for analysis EMSURE® ACS Merck 1011881000 1 KG Ammonium nitrate for analysis EMSURE® ACS Merck 1011885000 5 KG Ammonium peroxodisulfate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1012010500 500 G Ammonium peroxodisulfate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1012011000 1 KG Ammonium peroxodisulfate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1012015000 5 KG Ammonium peroxodisulfate for analysis EMSURE® ACS,Reag. Ph Eur Merck 1012019012 12KG Ammonium sulfate for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1012170100 100 G Ammonium sulfate for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1012171000 1 KG Ammonium sulfate for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1012175000 5 KG Ammonium sulfate for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1012179025 25 KG Ammonium thiocyanate for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1012130500 500 G Ammonium thiocyanate for analysis EMSURE® ACS,ISO,Reag. Ph Eur Merck 1012139025 25 KG Aniline for analysis EMSURE® Merck 1012611000 1 L Antimony(III) chloride for analysis EMSURE® ACS Merck 1078380250 250 G Antimony(III) chloride for analysis EMSURE® ACS Merck 1078381000 1 KG ANTIMONY(III) OXIDE FOR ANALYSIS EMSURE® Merck 1078360100 100 G ANTIMONY(III) OXIDE FOR ANALYSIS EMSURE® Merck 1078361000 1 KG BARBITURIC ACID FOR ANALYSIS EMSURE® Merck 1001320025 25 G BARBITURIC ACID FOR ANALYSIS EMSURE® Merck 1001320100 100 G Barium acetate for analysis EMSURE® ACS Merck 1017040500 500 G BARIUM CARBONATE FOR ANALYSIS EMSURE® ACS,REAG.
Load more

Recommended publications
  • Antimicrobial Resistance and Disinfectants Susceptibility of Persistent Bacteria in a Tertiary Care Hospital
    Journal of Microbiology and Antimicrobials Vol. 2(7), pp. xx-xx, October 2010 Available online http://www.academicjournals.org/JMA ISSN 2141-2308 ©2010 Academic Journals Full Length Research Paper Antimicrobial resistance and disinfectants susceptibility of persistent bacteria in a tertiary care hospital Maria Lucia Morcerf Bouzada1, Vania Lucia Silva1, Felipe Augusto Sa Moreira1, Girlene Alves Silva2 and Claudio Galuppo Diniz1* 1Department of Parasitology, Microbiology and Immunology, Laboratory of Bacterial Physiology and Molecular Genetics, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora/MG,36036-900, Brazil. 2Department of Applied Nursing, School of Nursing, Federal University of Juiz de Fora, Juiz de Fora/MG, 36036-900, Brazil. Accepted 22 October, 2010 It is well known that putative pathogenic bacteria are ubiquitous and widely distributed in the hospital environment. This study aimed to detect bacterial persistence in the nosocomial environment (different critical areas of the hospital) after mopping by the cleaning staff. Susceptibility patterns to antimicrobial drugs and disinfectants commonly used in health services were also investigated by disk diffusion and agar dilution tests. Rinse water from mops was processed for isolation of Enterobacteriaceae (GNR), non-fermenting Gram-negative rods (NFGNR), coagulase-negative staphylococci (CNS) and enterococci (ENT). Microorganisms were biochemically characterized and 547 strains were recovered. Only CNS and NFGNR were isolated in all critical areas. Overall 67% of the isolated bacteria were resistant to more than three drugs, being considered as multiresistant. Disinfectants were effective in concentrations ranging from 0.125 to 1%. Hospitals provide reservoirs of multiresistant microorganisms borne by patients and staff, but the hospital environment may be an important repository.
    [Show full text]
  • Detailed Teacher Instructions: Inheritance, X-Linkage, Evolution Over Multiple Generations, Genetic Hitchhiking
    Revised Laboratory on Molecular Evolution Gredler et al. (2015) Detailed Teacher Instructions: Inheritance, X-linkage, Evolution over Multiple Generations, Genetic Hitchhiking Objectives: Between the laboratory exercise and the associated lectures, students will be able to: Explain the process of evolution by natural selection in terms of fitness-related traits and allele frequencies Describe the concept of X-linked inheritance Perform DNA extractions, PCR, and gel electrophoresis Analyze molecular data as a means of understanding an evolutionary process Explain the concepts of selective sweeps, hitchhiking, and linkage Materials: Drosophila melanogaster heat shock white-eyed strain 60739 Drosophila melanogaster heat shock white-eyed strain 60740 Drosophila melanogaster Zimbabwe (wild type) strain 60741 Culture vials, plugs, and food (media) for Drosophila rearing Carolina Biological FlyNap® Anesthetic Kit: 173010 (Optional but strongly preferred) CO2 anesthetization facilities for Drosophila DNA extraction buffer and proteinase-K for DNA isolation Sorting brushes "Squishing buffer" and proteinase-K for DNA isolation Equipment and reagents for polymerase chain reaction including oligonucleotides for "NEAR" and "FAR" markers Equipment and reagents for agarose gel electrophoresis Magnifying glasses Sharpie markers Custom PowerPoints and projector, if desired 1 Revised Laboratory on Molecular Evolution Gredler et al. (2015) This exercise allows students to view evolution over multiple generations, experiment with molecular techniques, and learn concepts of molecular evolution. This exercise requires considerable advance preparation (must be started approximately 6 weeks before planned class start date, with initial white- eyed fly crosses starting approximately 4 weeks before the planned class start date). The supplies and directions are listed out so that you may purchase or use supplies you already have.
    [Show full text]
  • Identification of Genes Involved in Acid Tolerance, Antimicrobial Resistance and Virulence of Enterococcus Faecium
    Identification of genes involved in acid tolerance, antimicrobial resistance and virulence of Enterococcus faecium Thesis submitted by Hashimatul Fatma binti Hashim For the degree of DOCTOR OF PHILOSOPHY in the Faculty of Medical Sciences University College London Division of Microbial Diseases UCL Eastman Dental Institute 256 Gray’s Inn Road London WC1X 8LD UK 2016 Declaration I hereby certify that the work embodied in this thesis is the result of my own investigation, except where otherwise stated. 2 Abstract Enterococcus faecium is an opportunistic human nosocomial pathogen that has developed resistance to many existing antimicrobial therapies. Treatment of enterococcal infections is becoming increasingly challenging and there are limited therapeutic options against multidrug-resistant enterococci. The work described in this thesis aimed to identify genes involved in resistance to host stresses and virulence as these could potentially be future therapeutic targets. An E. faecium transposon mutant library was screened for altered resistance to lysozyme and to nisin as a model antimicrobial peptide. This approach led to the identification of several genes that contribute to lysozyme and nisin resistance. A number of mutants that were sensitive to nisin had a transposon insertion in a gene predicted to encode a tyrosine decarboxylase. It was shown that the tyrosine decarboxylase plays a role in acid tolerance and mediates virulence of E. faecium in a Galleria mellonella larvae infection model. A targeted genetic approach was used to examine the role of an E. faecium serine threonine protein kinase (Stk1) in antimicrobials resistance, host cell stresses and virulence. Disruption of the stk1 gene led to higher sensitivity to antibiotics that target the penicillin- binding proteins and bile salts compared to the wild type.
    [Show full text]
  • Clinical Review Nicholas Rister, MD NDA 021572 Cubicin (Daptomycin for Injection)
    Clinical Review Nicholas Rister, MD NDA 021572 Cubicin (Daptomycin for injection) CLINICAL REVIEW Application Type NDA supplement Application Number(s) 21572 Priority or Standard Priority Submit Date(s) March 1, 2017 Received Date(s) March 2, 2017 PDUFA Goal Date September 2, 2017 Division / Office DAIP/OAP Reviewer Name(s) Nicholas Rister, MD Review Completion Date August 4, 2017 Established Name Daptomycin (Proposed) Trade Name Cubicin Therapeutic Class Cyclic Lipopeptide Applicant Cubist Pharmaceuticals Formulation(s) Injection Dosing Regimen 7 mg/kg (12-17 years), 9 mg/kg (7-11 years), and 12 mg/kg (1-6 years) Indication(s) Bacteremia caused by Staphylococcus aureus Intended Population(s) Ages 1-17 years 1 Reference ID: 4142515 Clinical Review Nicholas Rister, MD NDA 021572 Cubicin (Daptomycin for injection) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 7 1.1 Recommendation on Regulatory Action ............................................................. 7 1.2 Risk Benefit Assessment .................................................................................... 7 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 8 1.4 Recommendations for Postmarket Requirements and Commitments ................ 8 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 8 2.1 Product Information ............................................................................................ 8 2.2 Tables of Currently Available Treatments
    [Show full text]
  • REPOSITORY of RESEARCH SYNOPSES for M.PHIL DEGREE PRESENTED to ASRB of UHS
    REPOSITORY OF RESEARCH SYNOPSES FOR M.PHIL DEGREE PRESENTED To ASRB Of UHS Degree Student Name InstituteResearch Title Supervisor Report Status M.Phil Anatomy Dr Amer Qayum RMC Rawalpindi Morphology of human ascending aortic fold Prof. Tassaduq Hussain Sheikh Approved Dr. Ahmad Farzad M.Phil Anatomy UHS Lahore Effect of vitamin E on nephrotoxicity in methimazole induced hypothyroidism in albino mice Prof. Dr. Khalid Parvez Lone Approved Qureshi Dr. Aisha M.Phil Anatomy UHS Lahore Effect of Cinnamon bark oil on Cadmium induced testicular toxicity in adult male albino rats Prof. Dr. Muhammad Tahir Approved Muhammad Effect Of Citrullus colocynthis aqueous seed extract on beta cell regeneration and intra-islet M.Phil Anatomy Dr. Alia Amin UHS Lahore Prof. Dr. Muhammad Tahir Approved vasculature in alloxan induced diabetic male albino rats M.Phil Anatomy Dr. Alvia Batool PGMI Lahore Weight and histological changes induced by ribavirin in the testes of albino rats Prof. Dr. Fozia Farzana Approved The effects of Ficus carica L. (Anjir) leaf extract on gentamicin induced nephrotoxicity in adult M.Phil Anatomy Dr. Ammara Ghafoor UHS Lahore Prof. Dr. Khalid Parvez Lone Approved male albino mice Protective effect of aqueous extract of Carica papaya L. seeds on neproxen induced M.Phil Anatomy Dr. Ammara Riaz UHS Lahore Prof. Dr. Muhammad Tahir Approved nephrotoxicity in rats Histopathological effects of omeprazole on kidney of albino rats in different doses and M.Phil Anatomy Dr. Amna Mubeen PGMI Lahore Prof. Dr. Fozia Farzana Approved duration M.Phil Anatomy Dr. Aneeqa Chughtai UHS Lahore Anatomical variations of placentae in healthy pregnancies among local population Prof.
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Name of the substance Sodium tungstate Identification number 13472-45-2 (CAS number) Synonyms SODIUM TUNGSTATE * Tungstic acid, Disodium salt Issue date 18-May-2015 Version number 02 Revision date 14-July-2015 Supersedes date 18-May-2015 1.2. Relevant identified uses of the substance or mixture and uses advised against Identified uses Not available. Uses advised against None known. 1.3. Details of the supplier of the safety data sheet Supplier Company name Materion Advanced Chemicals Inc. Address 407 N. 13th Street 1316 W. St. Paul Avenue Milwaukee, WI 53233 United States Division Milwaukee Telephone 414.212.0257 e-mail [email protected] Contact person Noreen Atkinson 1.4. Emergency telephone number SECTION 2: Hazards identification 2.1. Classification of the substance or mixture The substance has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies. Classification according to Directive 67/548/EEC or 1999/45/EC as amended Classification Xn;R22, R52/53 The full text for all R-phrases is displayed in section 16. Classification according to Regulation (EC) No 1272/2008 as amended Health hazards Acute toxicity, oral Category 4 H302 - Harmful if swallowed. H302 - Harmful if swallowed. Environmental hazards Hazardous to the aquatic environment, Category 3 H412 - Harmful to aquatic life with long-term aquatic hazard long lasting effects. Hazard summary Physical hazards Not classified for physical hazards. Health hazards Harmful if swallowed. Occupational exposure to the substance or mixture may cause adverse health effects.
    [Show full text]
  • IN a PACK SIZE of 100Ml 2 3,3 DIAMINOBENZIDINE TETRAHYDROCHLORIDE, in a PACK SIZE of 5Gm
    Item NAME OF THE ITEM No. Group 1 Pathology 1 2 MERCAPTOETHANOL (2-ME), IN A PACK SIZE OF 100ml 2 3,3 DIAMINOBENZIDINE TETRAHYDROCHLORIDE, IN A PACK SIZE OF 5gm 3 A.P.T.T WITH CALCIUM CHLORIDE (LIQUID STABLE), IN A PACK SIZE OF 1 X 3ml 4 A.P.T.T WITH CALCIUM CHLORIDE (LIQUID STABLE), IN A PACK SIZE OF 1 X 4 ml 5 ACETIC ACID GLACIAL (AR), IN A PACK SIZE OF 2.5 LITRES 6 ACETIC ACID GLACIAL (AR), IN A PACK SIZE OF 500ml 7 ACETONE, IN A PACK SIZE OF 2.5 LITRES 8 ACETONE, IN A PACK SIZE OF 500ml 9 ACID FUSCHIN, IN A PACK SIZE OF 25gm 10 ACTIVATED CHARCOAL, 500 gm 11 AET (2-AMINOETHYL ISO THIOURANIUMBROMIDE) 100 gm 12 ALCIAN BLUE, IN A PACK SIZE OF 5gm 13 ALUMINIUM CHLORIDE ANHYDROUS, IN A PACK SIZE OF 500gm 14 ALUMINIUM HYDROXIDE, IN A PACK SIZE OF 500gm 15 ALUMINIUM SULPHATE 500gm 16 AMMONIUM FERROUS SULPHATE 500gm 17 AMMONIUM OXALATE, IN A PACK SIZE OF 500gm ANTI - A ANTISERA MONOCLONAL 18 AVIDITY - 3-4 SECONDS TITRE - 1:256 IN A PACK SIZE OF 6 X 10 ml ANTI - B ANTISERA MONOCLONAL 19 AVIDITY - 3-4 SECONDS TITRE - 1:256 , IN A PACK SIZE OF 6 X 10 ml ANTI - D Igm MONOCLONAL 20 AVIDITY - 5-10 SECONDS TITRE - 1:128 , IN A PACK SIZE OF 6 X 10 ml ANTI - D Igm + IgG BLEND 21 AVIDITY - 10-20 SECONDS TITRE - 1:256 IN A PACK SIZE OF 6 X 10 ml 22 APTT CONTROL , IN A PACK SIZE OF 12 X 1 ml 23 Aqueous Borax 125 ml Page 1 of 52 24 Borax Carmine Powder 25 gm 25 Ammonium Sulphate Crystals 500gm 26 BARIUM CHLORIDE (AR), IN A PACK SIZE OF 500gm 27 BASIC FUSCHIN, IN A PACK SIZE OF 25gm 28 BENEDICT'S REAGENT (QUALITATIVE), IN A PACK SIZE OF 5LITRES 29 BENZIDINE, IN A PACK SIZE OF 50gm 30 BIEBRICH SCARLET, IN A PACK SIZE OF 25gm 31 BRILLIANT CRESYL BLUE (POWDER), IN A PACK SIZE OF 25gm 32 BRILLIANT CRESYL BLUE (SOLN.), IN A PACK SIZE OF 100 ml 33 BROMELAINE Lowest Pack Size 34 CALCIUM CHLORIDE ANHYDROUS, IN A PACK SIZE OF 500gm.
    [Show full text]
  • Quinupristin/Dalfopristin
    Reprinted from www.antimicrobe.org Quinupristin/Dalfopristin Antibiotic Class: Streptogramin Antimicrobial Activity: Gram-positive bacteria. In-vitro data suggests streptogramins possess activity against gram-negative upper respiratory tract pathogens and gram-negative anaerobes. Mechanism of Action: Inhibition of mRNA translation by binding to the 50S subunit of bacterial ribosomes. Pharmacodynamics: Predominantly independent of concentration once above four times the MIC of common Staphylococci and Streptococci. Pharmacokinetics: (7.5mg/kg dose at steady state) Cmax: 3.2 and 7.96mg/L (quinupristin and dalfopristin respectively) Half-life: 3.07 and 1.04 hours (quinupristin and dalfopristin respectively) Volume of distribution: 0.45 and 0.24L/kg (quinupristin and dalfopristin respectively) Adverse Effects: Venous irritation due to quinupristin/dalfopristin is common. In comparative trials approximately 40% of patients experienced infusion site adverse reactions compared to 25% of comparator treated patients. Increasing the infusion volume or administering the drug via central line may attenuate this reaction. In two compassionate use studies, arthralgias (9.1%) and myalgias (6.6%) were the most common adverse event related to quinupristin/dalfopristin. Hyperbilirubinemia was documented in up to 25% of quinupristin/dalfopristin treated patients in compassionate use/non-comparative studies. Dosage: Intravenous only – available as 500mg (150mg quinupristin and 350mg dalfopristin) and 600mg (180mg quinupristin and 420mg dalfopristin) powder for reconstitution vials Serious or life-threatening infections associated with vancomycin-resistant Enterococcus faecium – 7.5mg/kg every 8 hours Complicated skin and skin structure infection caused by methicillin-susceptible S. aureus or S. pyogenes – 7.5mg/kg every 12 hours Disease state based dosing: Hepatic failure: Although no dosage official dosage adjustment recommendations exist, pharmacokinetic data in patients with hepatic cirrhosis (Childs-Pugh class A or B) suggest that dosage adjustments may be necessary.
    [Show full text]
  • Hiper® Protein Estimation Teaching Kit (Quantitative)
    U n z i p p i n g G e n e s P r o d u c t I n f o r m a t i o n HiPer® Protein Estimation Teaching Kit (Quantitative) Product Code: HTBC005 Number of experiments that can be performed: 5 Duration of Experiment Protocol Biuret assay: 1 hour Folin – Lowry Assay: 2 hours Bradford assay: 1 hour Storage Instructions: The kit is stable for 12 months from the date of manufacture Store all the kit contents as specified in the brochure 1 Registered Office : Commercial Office 23, Vadhani Industrial Estate,LBS Marg, A-516, Swastik Disha Business Park, Tel: 00-91-22-6147 1919 15 WHO Mumbai - 400 086, India. Via Vadhani Indl. Est., LBS Marg, Fax: 6147 1920, 2500 5764 GMP Tel. : (022) 4017 9797 / 2500 1607 Mumbai - 400 086, India Email : [email protected] CERTIFIED Fax : (022) 2500 2286 Web : www.himedialabs.com The information contained herein is believed to be accurate and complete. However no warranty or guarantee whatsoever is made or is to be implied with respect to such information or with respect to any product, method or apparatus referred to herein Index Sr. No. Contents Page No. 1 Aim 3 2 Introduction 3 3 Materials Required But Not Provided 3 4 Storage 3 5 Biuret Assay 3 Principle Kit contents Important Instructions Procedure Observation and Result Interpretation 6 Folin – Ciocalteau (Lowry) Assay 6 Principle Kit contents Important Instructions Procedure Observation and Result Interpretation 7 Dye Binding (Bradford) Assay 9 Principle Kit contents Important Instructions Procedure Observation and Result Interpretation 8 Troubleshooting Guide 12 2 Aim: To determine the concentration of a protein by three commonly used methods: 1.
    [Show full text]
  • Free of Cost CONTENTS Tender Letter Terms & Conditions with Annexure Check List of the Documents Item Schedule
    ESIC E-TENDER ENQUIRY FORM FOR SUPPLY OF LAB REAGENTS, CHEMICAL AND KITS E-Tender Enquiry Form – Free of cost CONTENTS Tender Letter Terms & Conditions with Annexure Check List of the Documents Item Schedule EMPLOYEE’S STATE INSURANCE CORPORATION MEDICAL COLLEGE & HOSPITAL, NH-3 NIT FARIDABAD-121001 LAST DATE OF SUBMISSION OF ONLINE: 09/08/2021 For any further clarifications/queries for e-Procurement Portal, Please contact at: 0129-2970111 CPPP Id for Support / Helpdesk -https://eprocure.gov.in/eprocure/app ESIC Medical College and Hospital NH-3, Faridabad, Haryana- 121001 Tel No: 0129-4156471, Website: www.esic.nic.in E- Tender Enquiry No.134/U/16/30/R.C Lab, Chemical & Kits /2021-Med. Store, Dated:19/07/2021 Dean, ESIC Medical College & Hospital, NH-3, NIT Faridabad invites online e-Tender for the Rate Contract for supply of LAB REAGENTS, CHEMICAL AND KITS, through e- procurement portal- https://eprocure.gov.in/eprocure/app BRIEF OF ESIC RATE CONTRACT 1. It is proposed to enter into a Running Rate Contract with bidder(s)/ firm(s) which fulfill the eligibility criteria approved by Dean, ESIC Medical College & Hospital, NH-3, NIT Faridabad for supply of LAB REAGENTS, CHEMICAL AND KITS/ items enumerated in the schedule annexure B. The eligibility criteria have been given in the terms and conditions as annexure A. Bidder(s)/ Firm(s) intending to participate in the rate contract should first ensure that they fulfill all the eligibility criteria as prescribed under the terms and conditions, otherwise the tenders will be summarily rejected. 2. The Rate Contract will be governed by the terms and conditions enclosed with this Tender Enquiry and no modifications / alterations etc.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0285765 A1 Chung Et Al
    US 20150285765A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0285765 A1 Chung et al. (43) Pub. Date: Oct. 8, 2015 (54) ACTIVE TRANSPORT OF CHARGED (52) U.S. Cl. MOLECULES INTO, WITHIN, AND/OR FROM CPC. G0IN 27/44756 (2013.01); G0IN 27/44704 CHARGED MATRICES (2013.01); G0IN 27/44708 (2013.01) (71) Applicant: Massachusetts Institute of Technology, Cambridge, MA (US) (57) ABSTRACT (72) Inventors: Kwanghun Chung, Cambridge, MA (US); Sung-Yon Kim, Cambridge, MA Articles and methods for the active transport of molecules (US); Kimberly Ohn, Boston, MA (US); into, within, and/or from a matrix are generally described. In Evan Murray, Cambridge, MA (US); some embodiments, an electric field may be used to alter the Jae Hun Cho, Cambridge, MA (US) position of the molecule with respect to the matrix. The elec tric field may be used to move the molecule to a new location (73) Assignee: Massachusetts Institute of Technology, within the matrix, remove the molecule from the matrix, or Cambridge, MA (US) infuse the molecule into the matrix. For instance, the electric field may be used to move a molecule having a binding (21) Appl. No.: 14/678,660 partner within the matrix into or away from the vicinity of the binding partner. In some embodiments, the position of the (22) Filed: Apr. 3, 2015 molecule may be altered by exposing the molecule to an electrodynamic field. In some Such embodiments, the mol Related U.S. Application Data ecule exposed to the dynamic electric field may have (60) Provisional application No.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
    [Show full text]